Longeveron to Host Key Opinion Leader Event on Medicinal Signaling Cells (MSCs) for Hypoplastic Left Heart Syndrome (HLHS) with Lomecel-B™ on August 16, 2023 - Longeveron (NASDAQ:LGVN)

MIAMI, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs,

Related Keywords

United States ,India ,Nebraska ,Japan ,Miami ,Florida ,American ,Sunjay Kaushal ,Vaughna Starnes ,Mike Moyer ,Ram Kumar Subramanyan ,Longeveron Lomecel ,Tomr Demeester ,Los Angeles ,Northwestern University Feinberg School Of Medicine ,Longeveron Inc ,Phd Northwestern University Feinberg School Of Medicine ,National Institutes Of Health ,Workforce On National Databases ,Thoracic Surgical Association ,Longeveron Co ,Exchange Commission On ,Exchange Commission ,Longeveron Or Company ,American Heart Association ,University Of Southern California ,Northwestern University Feinberg School ,Pediatric Cardiothoracic Surgery ,Medical Center ,Nebraska Medical Center ,Hypoplastic Left Heart Syndrome ,Medicinal Signaling Cells ,Longeveron Co Founder ,Chief Scientific Officer ,Wa El Hashad ,Longeveron Chief Executive Officer ,National Institutes ,General Surgery ,Southern California ,Thoracic Surgery ,Congenital Cardiac Surgery ,Hospital Los Angeles ,Nebraska Medical ,Cardiovascular Surgery ,Western Thoracic Surgical Association ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Report ,